Inflammopharmacology impact factor, indexing, ranking (2024)


inflammopharmacology

Aim and Scope

The Inflammopharmacology is a research journal that publishes research related to Immunology and Microbiology; Medicine; Pharmacology, Toxicology and Pharmaceutics. This journal is published by the Birkhauser Verlag Basel. The ISSN of this journal is 09254692, 15685608. Based on the Scopus data, the SCImago Journal Rank (SJR) of inflammopharmacology is 0.932.

Also, please check the following important details about inflammopharmacology: Publisher, ISSN, Ranking, Indexing, Impact Factor (if applicable), Publication fee (APC), Review Time, and Acceptance Rate.

According to Clarivate's JCR, journals indexed in SCIE/SSCI have an impact factor.

Inflammopharmacology Ranking

Impact Factor: 5.093
Total Citations: 3755
SJR (SCImago Journal Rank): 0.932
Quartile: Q1

The Impact Factor of Inflammopharmacology is 5.093.

The impact factor (IF) is a measure of the frequency with which the average article in a journal has been cited in a particular year. It is used to measure the importance or rank of a journal by calculating the times its articles are cited.

The impact factor was devised by Eugene Garfield, the founder of the Institute for Scientific Information (ISI) in Philadelphia. Impact factors began to be calculated yearly starting from 1975 for journals listed in the Journal Citation Reports (JCR). ISI was acquired by Thomson Scientific & Healthcare in 1992, and became known as Thomson ISI. In 2018, Thomson-Reuters spun off and sold ISI to Onex Corporation and Baring Private Equity Asia. They founded a new corporation, Clarivate, which is now the publisher of the JCR.


Important Metrics

Journal Title: Inflammopharmacology
Publisher: Birkhauser Verlag Basel
ISSN: 09254692, 15685608
Type: journal
Journal Scope: Immunology and Microbiology; Medicine; Pharmacology, Toxicology and Pharmaceutics
Country: Switzerland
H-Index: 61
SJR: 0.932
Quartile: Pharmacology (Q1); Pharmacology (medical) (Q1); Immunology (Q2)

inflammopharmacology Indexing

The inflammopharmacology is indexed in:

An indexed journal means that the journal has gone through and passed a review process of certain requirements done by a journal indexer.

The Web of Science Core Collection includes the Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts & Humanities Citation Index (AHCI), and Emerging Sources Citation Index (ESCI).


Inflammopharmacology Impact Factor 2024

The latest impact factor of inflammopharmacology is 5.093.

The impact factor (IF) is a measure of the frequency with which the average article in a journal has been cited in a particular year. It is used to measure the importance or rank of a journal by calculating the times it's articles are cited.

Note: Every year, The Clarivate releases the Journal Citation Report (JCR). The JCR provides information about academic journals including impact factor. The latest JCR was released in June, 2023. The JCR 2024 will be released in the June 2024.


Inflammopharmacology Quartile

The latest Quartile of inflammopharmacology is Q1.

Each subject category of journals is divided into four quartiles: Q1, Q2, Q3, Q4. Q1 is occupied by the top 25% of journals in the list; Q2 is occupied by journals in the 25 to 50% group; Q3 is occupied by journals in the 50 to 75% group and Q4 is occupied by journals in the 75 to 100% group.



Call for Papers

Visit to the official website of the journal/ conference to check the details about call for papers.

How to publish in Inflammopharmacology?

If your research is related to Immunology and Microbiology; Medicine; Pharmacology, Toxicology and Pharmaceutics, then visit the official website of inflammopharmacology and send your manuscript.

Tips for publishing in Inflammopharmacology:

Acceptance Rate

Acceptance rate is the ratio of the number of articles submitted to the number of articles published. Researchers can check the acceptance rate on the journal website. Alternatively, they can contact the editor of the journal.

Journal Publication Time

The publication time may vary depending on factors such as the complexity of the research and the current workload of the editorial team. Journals typically request reviewers to submit their reviews within 3-4 weeks. However, some journals lack mechanisms to enforce this deadline, making it difficult to predict the duration of the peer review process.

The review time also depends upon the quality of the research paper.


Final Summary

  • The impact factor of inflammopharmacology is 5.093.
  • The inflammopharmacology is a reputed research journal.
  • It is published by Birkhauser Verlag Basel.
  • The journal is indexed in UGC CARE, Scopus, SCIE, PubMed.
  • The (SJR) SCImago Journal Rank is 0.932.

Sources: inflammopharmacology







SIMILIAR JOURNALS


JOURNAL OF ANTIBIOTICS

ISSN: 0021-8820
Publisher: SPRINGERNATURE

IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

ISSN: 0892-3973
Publisher: TAYLOR & FRANCIS LTD

REGULATORY TOXICOLOGY AND PHARMACOLOGY

ISSN: 0273-2300
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE

FOOD AND AGRICULTURAL IMMUNOLOGY

ISSN: 0954-0105
Publisher: TAYLOR & FRANCIS LTD

INFLAMMOPHARMACOLOGY

ISSN: 0925-4692
Publisher: SPRINGER BASEL AG

INNATE IMMUNITY

ISSN: 1753-4259
Publisher: SAGE PUBLICATIONS LTD

BIOMARKERS

ISSN: 1354-750X
Publisher: TAYLOR & FRANCIS LTD

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

ISSN: 1386-1964
Publisher: ELSEVIER

MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS

ISSN: 1383-5718
Publisher: ELSEVIER

MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH

ISSN: 1383-5742
Publisher: ELSEVIER

TOP RESEARCH JOURNALS

Credit and Source: Scopus, Clarivate, UGC CARE.